Abstract Background and Purpose Millions of patients with inflammatory diseases are
treated with tumour necrosis factor (TNF) inhibitors (TNFi). Individual treatment response …

Hypothesis While conventional in silico immunogenicity risk assessments focus on
measuring immunogenicity based on the potential of therapeutic proteins to be processed …

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal
tract with increasing incidence worldwide. Although a deeper understanding of the …

Biosimilars of anti-TNF-α inhibitors have become a valid and usually less expensive
alternative to their originator drugs [1]. Therefore, switching from originator to biosimilar …

Therapeutic Abs directed toward TNF-α display significant immunogenicity in humans,
frequently leading to lower serum concentrations of the Ab that are associated with lower …

Introduction Noninfectious uveitis related to systemic inflammatory diseases represents a
leading cause of blindness. Anti-TNFα agents are the first-line biologic therapy after …

Objective The objective of this study was to ascertain pegloticase persistence and adverse
events associated with concomitant immunomodulatory drug treatment in patients with gout …

Broadly neutralising antibodies (bNAbs) may play an important role in future strategies for
HIV control. The development of anti-drug antibody (ADA) responses can reduce the efficacy …

Background Adalimumab, a tumor necrosis factor-α inhibitor, is a biologic used for the
treatment of moderate-to-severe hidradenitis suppurativa (HS). It is well known that patients …

Juvenile idiopathic arthritis (JIA) is a chronic inflammatory disease affecting the joints and
other organs that occurs in 1 in 1,000 children in the United States. Given the various …